66 citations,
December 2018 in “Dermatology” Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
62 citations,
June 2015 in “The Journal of Dermatology” People with alopecia areata have more Th17 cells and fewer Treg cells, which may be key to the condition's development.
61 citations,
September 2010 in “Genomics” The study found that immune responses disrupt hair growth cycles, causing hair loss in alopecia areata.
60 citations,
September 2015 in “Expert Review of Clinical Immunology” Lymphocytes, especially CD8+ T cells, play a key role in causing alopecia areata, and targeting them may lead to new treatments.
59 citations,
September 2008 in “Experimental dermatology” Both mouse and rat models are effective for testing alopecia areata treatments.
57 citations,
April 2019 in “British journal of dermatology/British journal of dermatology, Supplement” Alopecia areata involves immune system imbalances that may lead to depression and anxiety.
52 citations,
March 2010 in “British Journal of Dermatology” Alopecia areata shows a unique type 1 interferon signature, suggesting potential treatment by targeting this pathway.
50 citations,
December 2009 in “Journal of The European Academy of Dermatology and Venereology” Latanoprost can effectively treat eyelash hair loss, with 45% of patients showing hair regrowth and no reported side effects.
48 citations,
May 1999 in “International Journal of Dermatology” Alopecia areata is an unpredictable autoimmune hair loss condition, treated based on severity, with half of patients regrowing hair within a year without treatment.
43 citations,
May 2011 in “Dermatologic Therapy” Recognizing the different stages of alopecia areata is crucial for accurate diagnosis and treatment.
42 citations,
November 2018 in “Archives of dermatological research” Apremilast was not effective in treating moderate-to-severe alopecia areata.
40 citations,
August 2022 in “Frontiers in immunology” Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.
39 citations,
January 2019 in “Journal of the American Academy of Dermatology” Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.
37 citations,
October 2017 in “Clinical and Experimental Dermatology” Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.
36 citations,
January 2015 in “Dermatology” Bimatoprost was found to be safer and more effective than mometasone furoate for treating scalp hair loss.
34 citations,
October 2017 in “Archivos Argentinos De Pediatria” Alopecia Areata is a complex, unpredictable autoimmune hair loss condition with limited treatment options and a significant psychological impact.
33 citations,
July 1992 in “Journal of Investigative Dermatology” Minoxidil doesn't affect perifollicular lymphoid infiltration in alopecia areata patients.
32 citations,
January 2005 in “Journal of The American Academy of Dermatology” Some babies are born with alopecia areata, and a treatment with clobetasol propionate can regrow hair in half of the cases.
26 citations,
October 2020 in “Pediatric Dermatology” Oral tofacitinib may effectively treat hair loss in children with alopecia areata.
26 citations,
August 2013 in “Australasian Journal of Dermatology” Certain scalp patterns can indicate the severity and activity of hair loss in Turkish alopecia patients.
25 citations,
October 2019 in “JAAD Case Reports” Baricitinib helped a woman with severe hair loss regrow almost all her hair without side effects.
25 citations,
December 2015 in “Journal of the European Academy of Dermatology and Venereology” Alopecia areata significantly lowers quality of life, especially in personal and social areas, and more so if the patient is also depressed.
23 citations,
September 2019 in “Journal of The American Academy of Dermatology” Tofacitinib and oral minoxidil together effectively regrow hair in severe alopecia areata patients.
23 citations,
August 2018 in “Anais Brasileiros De Dermatologia” Both androgenetic alopecia and alopecia areata negatively impact quality of life, with no significant difference between them.
23 citations,
March 2001 in “Clinics in dermatology” Alopecia areata involves immune response and gene changes affecting hair loss.
21 citations,
January 2014 in “International Journal of Trichology” The study concluded that yellow dots are a common and useful sign for diagnosing alopecia areata in dark-skinned individuals and may indicate the severity of the condition.
20 citations,
June 2019 in “Experimental Dermatology” The research suggests that autophagy-related genes might play a role in causing alopecia areata.
20 citations,
August 2018 in “Clinics in Dermatology” The conclusion is that understanding and addressing the psychological effects of alopecia areata is important for effective treatment.
20 citations,
January 2013 in “Evidence-based complementary and alternative medicine” TGPC plus CGT is effective and safe for treating severe alopecia areata in children.
20 citations,
June 2010 in “Genes and Immunity” Blood tests can help understand the genetic differences in people with alopecia areata, including how severe it is and if it's inherited.